Docoh
Loading...

NBIX Neurocrine Biosciences

APP
Utility
Gonadotropin-releasing Hormone Receptor Antagonists and Methods Relating Thereto
16 Sep 21
Graham BEATON, Mi CHEN, Timothy Richard COON, Todd EWING, Wanlong JIANG, Willy MOREE, Martin ROWBOTTOM, Warren WADE, Liren ZHAO, Richard LOWE, Nicole SMITH, Neil ASHWEEK, Yun-Fei ZHU
Filed: 18 Dec 20
APP
Utility
Methods for the Administration of Comt Inhibitors
22 Jul 21
Provided are methods of administering a catechol-O-methyltransferase (COMT) inhibitor chosen from opicapone, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a CYP2C8 substrate, such as repaglinide.
Gordon LOEWEN, Grace LIANG, Evan SMITH
Filed: 1 Apr 21
GRANT
Utility
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
6 Jul 21
Neil Ashweek, Nicole Harriott
Filed: 22 Jan 20
APP
Utility
Treatment of Hyperkinetic Movement Disorders
1 Jul 21
Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 15 Sep 20
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
22 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
GRANT
Utility
VMAT2 inhibitor compounds and compositions thereof
22 Jun 21
Nicole Harriott, Donald Hettinger, Shawn Branum, Jeffrey C. Culhane
Filed: 17 Apr 18
GRANT
Utility
Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
15 Jun 21
Nicole Harriott, Nicholas Pagano
Filed: 4 Nov 16
APP
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
10 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 17 Dec 20
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
8 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
Grace S. Liang, Christopher F. O'Brien, Dao Tuyet Thai-Cuarto
Filed: 3 Aug 20
GRANT
Utility
High dosage valbenazine formulation and compositions, methods, and kits related thereto
8 Jun 21
Solid pharmaceutical compositions with high drug loading are provided.
Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
Filed: 19 Oct 20
GRANT
Utility
Substituted triazoles and methods relating thereto
1 Jun 21
Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
Filed: 4 Jun 20
APP
Utility
Treatment of Congenital Adrenal Hyperplasia
13 May 21
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 20 Oct 20
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
4 May 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
APP
Utility
Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
22 Apr 21
Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (,S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
Christopher F. O`Brien, Dimitri E. Grigoriadis
Filed: 3 Jun 20
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
23 Mar 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
GRANT
Utility
Methods for the administration of certain VMAT2 inhibitors
9 Mar 21
Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
Gordon Raphael Loewen, Sha Rosa Luo
Filed: 10 Aug 20
GRANT
Utility
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
9 Mar 21
Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
Filed: 2 Jul 19
APP
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
25 Feb 21
Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
Gordon Raphael Loewen, Sha Rosa Luo
Filed: 10 Aug 20
APP
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
18 Feb 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 26 Oct 20
GRANT
Utility
Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
16 Feb 21
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li, Shawn Branum
Filed: 15 Jul 20
Patents are sorted by USPTO publication date, most recent first